. . . . "PLV-2"@en . . . . "Felypressin binds to the vasopressin receptor V1a. This causes contraction of the smooth muscle in the vascular bed, especially capillaries, small arterioles and venules."@en . . "2-(L-phenylalanine)-8-L-lysinevasopressin"@en . "For use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential."@en . . "Felypressinum"@en . . . "Felypressin"@en . . . . " "@en . "Felypressin"@en . "Felypressine"@en . "A synthetic nonapeptide comprising cysteinyl, phenylalanyl, phenylalanyl, glutaminyl, asparaginyl, cysteinyl, prolyl, lysyl, and glycinamide residues in sequence, with a disulfide bridge joining the two cysteine residues. Its antidiuretic effects are less than those of vasopressin. It is used as a vasoconstrictor in local anaesthetic injections for dental use, and is an ingredient of preparations that have been used for treatment of pain and inflammation of the mouth. [ChEBI]"@en . . . . "approved"@en . . "Felipresina"@en . . . . . "# Cecanho R, De Luca LA Jr, Ranali J: Cardiovascular effects of felypressin. Anesth Prog. 2006 Winter;53(4):119-25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17177590 "@en . . . . . "Boissonnas, R.and Guttmann, S.; U.S. Patent 3,232,923; February 1, 1966: assigned to Sandoz AG, Switzerland."@en . . . . . . . . . . "56-59-7"@en . . . . "Humans and other mammals"@en . .